Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted May 12, 2008
US Drug Stocks Edge Higher, But ImClone Falls On Downgrade
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: GLG Member Program Contributor
Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...
Posted May 12, 2008
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
Analysis of: Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market | www.pipelinereview.com
Author: GLG Member Program Contributor
Now that liquid Leukine (GM-CSF) has been withdrawn by Bayer, Amgen commands the North American G-CSF market with its Neupogen and Neulasta.  However, Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL) has been treating patients with a biosimilar G-CSF called Neukine since 2004.  And...
Donald Fleming Posted May 9, 2008
ASA404 approach in treating lung cancer
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors
Posted May 7, 2008
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: GLG Member Program Contributor
The fact that they had a very small phase I studay of 14 patients only.  This concerns me a bit.  Usualy you enrol at least 30-40 patients in a phase I trial
Posted May 7, 2008
Oncothyreon files investigational new drug application for PX-866 oncology compound
Analysis of: Oncothyreon files investigational new drug application for PX-866 oncology compound | www.pipelinereview.com
Author: GLG Member Program Contributor
PI-3-kinase inhibitors are the next class of anti-cancer drugs. 
Donald Fleming Posted May 7, 2008
Hedgehog pathwa drugs and chemotherapy
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE
Posted May 7, 2008
Cancer-Gene Test Boosts Myriad's Sales
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: GLG Member Program Contributor
Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind...
Posted May 6, 2008
Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
Posted May 6, 2008
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: GLG Member Program Contributor
The data from this phase Ib study will allow Proteolix to proceed with a phase II study of their novel proteasome inhibitor Carfilzomib in patients with advanced solid tumors.  Phase II studies are already underway investigating its activity in myeloma, the tumor type shown to be sensitive...
Posted May 6, 2008
AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
Analysis of: AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
An interesting randomized phase II trial of Gemzar (the current standard with Tarceva) vs imexon + Gemzar. BUT shouldn't it be compared to Gemzar/ Tarceva??
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 724

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses

Azilect
September 2, 2008

Byetta Saves Lives
September 2, 2008

The Devil Is in the Details
September 1, 2008

Dangers of Methadone Usage
August 28, 2008

Healthways A Market Downturn and Results
August 26, 2008

 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-05T13:45:17.290